AbbVie’s $10.9B Apogee deal strengthens immunology beyond Humira, adds Zumilokibart optionality, and may be undervalued. See ...

AbbVie gains attention as healthcare rotation highlights Skyrizi, Rinvoq, immunology growth, and portfolio strength beyond ...

AbbVie said on Monday it ⁠would ⁠buy Apogee Therapeutics for $10.9 billion, the ⁠company's largest buyout in more than five years, as it seeks to ​bolster its treatment pipeline for inflammatory ...

AbbVie said on Monday it would buy biotech Apogee ⁠Therapeutics for $10.9 billion, its largest buyout in more than five years.

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

On June 22, AbbVie announced that it would acquire Apogee Therapeutics (APGE +0.24%), a biotech company focused on developing medicines for immunological and inflammatory diseases. AbbVie will pay ...

Key market opportunities for SKYRIZI include its expansion across multiple indications such as psoriasis and IBD, showcasing best-in-class efficacy and strong clinical responses. Strategic positioning ...

By Padmanabhan Ananthan June 22 (Reuters) - AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, in its largest buyout in more than five years to strengthen its next-gen ...

A multi-billion-dollar cash offer and a 60% premium are on the table as AbbVie nears its biggest buyout in seven years.

According to India Ratings & Research, Shilpa has spent over Rs. 800 crore on R&D expenses during FY21-FY25, with capex of over Rs. 1,200 crore. Shilpa spends around 8 percent of its annual revenue on ...